Contracts › HDTRA124C0014
HDTRA124C0014: Oral Broad Spectrum Antiviral TLR7 Agonist for Treatment of Lassa Fever
Awarded to Primmune Therapeutics, Inc. by Defense Threat Reduction Agency.
$11.3Mobligated
$23.1Mpotential value
31 August 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HDTRA124C0014 |
|---|---|
| Awardee | Primmune Therapeutics, Inc. |
| Awarding agency | Defense Threat Reduction Agency |
| Awarding office | DEFENSE THREAT REDUCTION AGENCY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AC33 National Defense R&D Services; Defense-Related Activities; Experimental Development |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 30 January 2024 to 31 August 2026 |
| Potential end | 31 December 2027 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record